Douglas M. Willis

Array ( [id] => 19637411 [patent_doc_number] => 12168007 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-12-17 [patent_title] => Substituted piperazines as dopamine D3/D2 receptor modulators [patent_app_type] => utility [patent_app_number] => 18/409478 [patent_app_country] => US [patent_app_date] => 2024-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8538 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18409478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19631095 [patent_doc_number] => 20240409544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 18/401896 [patent_app_country] => US [patent_app_date] => 2024-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18401896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19692772 [patent_doc_number] => 20250011317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => ANTI-PROLIFERATIVE AGENTS [patent_app_type] => utility [patent_app_number] => 18/393274 [patent_app_country] => US [patent_app_date] => 2023-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56080 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18393274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19692772 [patent_doc_number] => 20250011317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => ANTI-PROLIFERATIVE AGENTS [patent_app_type] => utility [patent_app_number] => 18/393274 [patent_app_country] => US [patent_app_date] => 2023-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56080 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18393274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19151174 [patent_doc_number] => 11976070 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-05-07 [patent_title] => Substituted pyrimido[6aEUR(tm), 1aEUR(tm):2,3]imidazo[4,5-c][1,6]naphthyridines as CK2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/392679 [patent_app_country] => US [patent_app_date] => 2023-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8976 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18392679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380872 [patent_doc_number] => 20240270742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/545952 [patent_app_country] => US [patent_app_date] => 2023-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48196 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18545952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19884135 [patent_doc_number] => 12269827 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-04-08 [patent_title] => Substituted pyrazino[1',2':1,5]pyrazolo[4,3-c][1,6]naphthyridines as CK2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/545059 [patent_app_country] => US [patent_app_date] => 2023-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8857 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18545059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19316745 [patent_doc_number] => 20240238285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE [patent_app_type] => utility [patent_app_number] => 18/543923 [patent_app_country] => US [patent_app_date] => 2023-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19117 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18543923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097713 [patent_doc_number] => 20240116941 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => SOLID FORMS OF A HBV CORE PROTEIN ALLOSTERIC MODIFIER [patent_app_type] => utility [patent_app_number] => 18/539773 [patent_app_country] => US [patent_app_date] => 2023-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11499 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18539773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19504961 [patent_doc_number] => 12116372 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-10-15 [patent_title] => Process for preparing methyl 3-bromo-2-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)propanoate [patent_app_type] => utility [patent_app_number] => 18/539527 [patent_app_country] => US [patent_app_date] => 2023-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 3374 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18539527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19233703 [patent_doc_number] => 20240190895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 18/536817 [patent_app_country] => US [patent_app_date] => 2023-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45938 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18536817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20302408 [patent_doc_number] => 12448386 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Processes for the preparation of substituted 1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indoles [patent_app_type] => utility [patent_app_number] => 18/529046 [patent_app_country] => US [patent_app_date] => 2023-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13136 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18529046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19201446 [patent_doc_number] => 20240173345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDE AND NUCLEOSIDE FOR TREATING VIRAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 18/515989 [patent_app_country] => US [patent_app_date] => 2023-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62067 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18515989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19201446 [patent_doc_number] => 20240173345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDE AND NUCLEOSIDE FOR TREATING VIRAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 18/515989 [patent_app_country] => US [patent_app_date] => 2023-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62067 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18515989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19201446 [patent_doc_number] => 20240173345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDE AND NUCLEOSIDE FOR TREATING VIRAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 18/515989 [patent_app_country] => US [patent_app_date] => 2023-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62067 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18515989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19151180 [patent_doc_number] => 11976076 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-05-07 [patent_title] => Substituted 7,8-dihydropyrimido[4,5-d]pyrimidines as anti-tubercular agents [patent_app_type] => utility [patent_app_number] => 18/508503 [patent_app_country] => US [patent_app_date] => 2023-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6631 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18508503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19140350 [patent_doc_number] => 20240139127 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => SUBSTITUTED CYCLOALKANES FOR MANAGING NEPHROGENIC DIABETES INSIPIDUS [patent_app_type] => utility [patent_app_number] => 18/502729 [patent_app_country] => US [patent_app_date] => 2023-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -69 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18502729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127153 [patent_doc_number] => 20240132506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/386964 [patent_app_country] => US [patent_app_date] => 2023-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9661 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18386964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20302407 [patent_doc_number] => 12448385 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Substituted indazoles as IRAK4 inhibitors [patent_app_type] => utility [patent_app_number] => 18/500155 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 44946 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 326 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18500155 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20302407 [patent_doc_number] => 12448385 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Substituted indazoles as IRAK4 inhibitors [patent_app_type] => utility [patent_app_number] => 18/500155 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 44946 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 326 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18500155 [rel_patent_id] =>[rel_patent_doc_number] =>)